Flolan Veletri

Description

Flolan, Veletri (epoprostenol)

Background
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death (1). Epoprostenol is indicated for treatment of pulmonary arterial hypertension (PAH) which is classified by WHO as Group 1. Epoprostenol is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs) to improve exercise ability (1-2).

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)

**WHO Group 1: Pulmonary Arterial Hypertension (PAH)**
1.1 Idiopathic (IPAH)
1.2 Heritable PAH
   1.2.1 Germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2)
   1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary hemorrhagic telangiectasia), Smad 9, caveolin-1 (CAV1), potassium channel super family K member-3 (KCNK3)
   1.2.3 Unknown
1.3 Drug-and toxin-induced
1.4 Associated with:
   1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1’. Pulmonary vena-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
1”. Persistent pulmonary hypertension of the newborn (PPHN)

WHO Group 2: Pulmonary Hypertension Owing to Left Heart Disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

WHO Group 3: Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities

WHO Group 4: Chronic Thromboembolic Pulmonary Hypertension - CTEPH!

WHO Group 5: Pulmonary Hypertension with Unclear Multifactorial Mechanisms
5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher’s disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH

The American College of Chest Physicians (ACCP) has published an updated clinical practice guideline for treating PAH. These guidelines use the New York Heart Association (NYHA) functional classification of physical activity scale to classify PAH patients in classes I-IV based
on the severity of their symptoms (4). Epoprostenol is indicated for patients with NYHA Functional Class III or IV (1-2).

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>II</td>
<td>Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>III</td>
<td>Patients with pulmonary hypertension resulting in marked limitation of physical activity. These patients are comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>IV</td>
<td>Patients with pulmonary hypertension resulting in inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased by any physical activity.</td>
</tr>
</tbody>
</table>

**Regulatory Status**

FDA-approved indication: Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly (97%) patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (49%) or PAH associated with connective tissue diseases (51%) (1-2).

Some patients with pulmonary hypertension have developed pulmonary edema during dose initiation, which may be associated with pulmonary veno-occlusive disease. Epoprostenol should not be used chronically in patients who develop pulmonary edema during dose initiation (1-2).

Epoprostenol is associated with a variety of adverse effects, many of which can be dose-limiting such as hypotension, nausea, vomiting, flushing, and headache. Hemorrhage, thrombocytopenia, and sepsis have also been reported (1-2).

Epoprostenol is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction (1-2).

**Related policies**

Adcirca, Adempas, Letairis, Opsumit, Orenitram, Remodulin, Revatio, Tracleer, Tyvaso, Uptravi, Ventavis
Flolan and Veletri may be considered **medically necessary** for patients 18 years of age and older with primary pulmonary hypertension, WHO Group 1 and if the conditions indicated below are met.

Flolan and Veletri may be considered **investigational** in patients less than 18 years of age and for all other indications.

**Prior-Approval Requirements**

**Age**  
18 years of age or older

**Diagnoses**

Patient must have **BOTH** of the following

1. Pulmonary Arterial Hypertension (PAH) - **WHO Group I**

2. NYHA functional classification of physical activity - **Class III or IV**

**AND ALL** of the following:

   a. **NO** congestive heart failure (CHF) due to severe left ventricular systolic dysfunction
   b. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed

**Prior – Approval Renewal Requirements**

**Age**  
18 years of age or older

**Diagnoses**

Patient must have the following

1. Pulmonary Arterial Hypertension (PAH) - **WHO Group I**
AND ALL of the following:
   a. Symptoms have improved or stabilized
   b. NO congestive heart failure (CHF) due to severe left ventricular systolic dysfunction
   c. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed

Policy Guidelines

Pre - PA Allowance
None

Prior - Approval Limits
Duration 2 years

Prior – Approval Renewal Limits
Same as above

Rationale

Summary
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death. Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) and NYHA functional class III or IV to improve exercise capacity (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Flolan/Veletri while maintaining optimal therapeutic outcomes.

References
5.40.15

Section: Prescription Drugs
Subsection: Cardiovascular Agents
Subject: Flolan Veletri
Effective Date: October 1, 2019
Original Policy Date: June 9, 2011
Page: 6 of 6


Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2012</td>
<td>Added NOT have congestive heart failure due to severe left ventricular systolic dysfunction.</td>
</tr>
<tr>
<td>March 2013</td>
<td>Annual editorial review and reference update.</td>
</tr>
<tr>
<td>March 2014</td>
<td>Annual review</td>
</tr>
<tr>
<td>June 2016</td>
<td>Annual editorial review and reference update. Addition of 18 years of age and prescriber agrees to monitor for pulmonary edema and discontinue if confirmed.</td>
</tr>
<tr>
<td>September 2017</td>
<td>Annual editorial review and reference update.</td>
</tr>
<tr>
<td>September 2018</td>
<td>Annual editorial review and reference update.</td>
</tr>
<tr>
<td>September 2019</td>
<td>Annual editorial review and reference update. Changed approval duration from lifetime to 2 years</td>
</tr>
</tbody>
</table>

Keywords

This policy was approved by the FEP® Pharmacy Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.